A universal respiratory detector for detecting a respiratory gas. The universal respiratory detector may include a plurality of layers with a visual indicator to quickly and reversibly change color to detect a respiratory gas parameter such as carbon dioxide. The color change may be visible from both sides of the detector. In some examples, the respiratory detector may be a biocompatible and conformable sticker for mounting on a person's face or an oxygen delivery device.

A minimal weight patient interface device that delivers breathing gas to a user includes a cushion assembling including a support cushion assembly and a sealing member is described herein. In one exemplary embodiment, the support cushion assembly includes a wedge that is made of a high density foam received within a wedge receiving portion of the support cushion assembly. In the exemplary embodiment, the cushion assembly is formed by the sealing member fitting over the support cushion assembly. The sealing member, in one embodiment, is made of silicone, for example, having a low durometer value (e.g., between 5-10 Shore 00). Furthermore, in one embodiment, the patient interface device also includes a faceplate that is placed over the cushion assembly and is made of a thermoform, such as a high density foam laminated between two pieces of fabric, such as polyester.

Provided according to embodiments of the present invention are methods of monitoring individuals that include securing a photoplethysmography probe to at least one of a pre-auricular region and a post-auricular region of the individual and obtaining photoplethysmography signals from the photoplethysmography probe. Photoplethysmography probes and helmets related to such methods are also described herein.

The present invention relates to a device for applying energy to a human body. The device comprises a contact surface which defines an application region in which a human body can be placed in the effective range of the energy. The device further comprises at least one means for outputting the energy directed substantially onto the application region, and at least one means for generating a vapour mixture comprising at least one cannabinoid. The device according to the invention also comprises at least one means for guiding the vapour mixture, which has an effective dose of at least one cannabinoid, into the surroundings of the breathing orifices of a human body. The present invention further relates to a method for operating such a device, and to the use of vapour mixtures comprising at least one cannabinoid in designated devices.

A customizable mask including a conforming seal is configured to utilize the physical process of granular jamming to enable it to adapt to a wide range of facial geometries. The mask may include a frame having a perimeter and a conduit connection, a conforming seal positioned along the perimeter of the frame. The conforming seal may include a sealing surface and a connecting surface, the connecting surface configured to mate with the perimeter of the frame, and the sealing surface configured to conform to a users' face. The conforming seal may further include an outer casing, granular material contained within the outer casing, and a vacuum connection. The mask may also include a similarly configured conforming frame. Further disclosed are methods of forming such masks.

The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

A stand-alone chamber or multi-chamber inhalation system has at least two alternative vaporized test liquid supply systems for passive or self-administered delivery of vaporized test fluid and air to one or more test chambers, which can be passive or restraint chambers, based on operator selection of delivery on and off times in a passive mode or actuation of an actuator in the chamber by a test animal in a self-administered mode. In one case, a multiple inhalation chamber system has two or more separate test fluid delivery systems and provides options for selective passive uniform drug delivery to multiple chambers or selective delivery of two or more different drugs to different groups of chambers from different delivery systems so that two different drugs or different concentrations of delivered drugs can be tested simultaneously.

A stand-alone chamber or multi-chamber inhalation system has at least two alternative vaporized test liquid supply systems for passive or self-administered delivery of vaporized test fluid and air to one or more test chambers, which can be passive or restraint chambers, based on operator selection of delivery on and off times in a passive mode or actuation of an actuator in the chamber by a test animal in a self-administered mode. In one case, a multiple inhalation chamber system has two or more separate test fluid delivery systems and provides options for selective passive uniform drug delivery to multiple chambers or selective delivery of two or more different drugs to different groups of chambers from different delivery systems so that two different drugs or different concentrations of delivered drugs can be tested simultaneously.

A personal respiratory isolation system (PRIS) provides a personal, negative pressure environment for a patient or user that reduces contamination and spread of pathogens exhaled by the patient into the environment. The PRIS includes an enclosure to receive the patient's head (such as a hood and a drape) and a negative pressure source which draws ambient air into the interior of the enclosure and draws air within the enclosure's interior (including the exhalations of the patient, including any contaminants and/or pathogens) out of the enclosure via a fluid port into a container for biohazard processing or disposal. The PRIS may allow positive air pressure therapeutic treatments to be delivered to the patient within the negative pressure environment, and the PRIS may maintain a constant pressure within the interior of the enclosure. The PRIS may include a transparent, hinged face shield for ease of patient observation and/or access.

A positive exhalation pressure device increases the pressure gradient in the airways, thereby increasing oxygen saturation levels and decreasing the severity of hypoxia. Various embodiments of the device may be inserted into the nasal and/or oral cavities, or configured as mask devices covering the nasal and/or oral cavities. In some embodiments, the resistance of the device may be varied.